Skip to content

Advertisement

  • Research article
  • Open Access

Novel Plasmodium falciparum metabolic network reconstruction identifies shifts associated with clinical antimalarial resistance

BMC Genomics201718:543

https://doi.org/10.1186/s12864-017-3905-1

  • Received: 23 March 2017
  • Accepted: 27 June 2017
  • Published:

Abstract

Background

Malaria remains a major public health burden and resistance has emerged to every antimalarial on the market, including the frontline drug, artemisinin. Our limited understanding of Plasmodium biology hinders the elucidation of resistance mechanisms. In this regard, systems biology approaches can facilitate the integration of existing experimental knowledge and further understanding of these mechanisms.

Results

Here, we developed a novel genome-scale metabolic network reconstruction, iPfal17, of the asexual blood-stage P. falciparum parasite to expand our understanding of metabolic changes that support resistance. We identified 11 metabolic tasks to evaluate iPfal17 performance. Flux balance analysis and simulation of gene knockouts and enzyme inhibition predict candidate drug targets unique to resistant parasites. Moreover, integration of clinical parasite transcriptomes into the iPfal17 reconstruction reveals patterns associated with antimalarial resistance. These results predict that artemisinin sensitive and resistant parasites differentially utilize scavenging and biosynthetic pathways for multiple essential metabolites, including folate and polyamines. Our findings are consistent with experimental literature, while generating novel hypotheses about artemisinin resistance and parasite biology. We detect evidence that resistant parasites maintain greater metabolic flexibility, perhaps representing an incomplete transition to the metabolic state most appropriate for nutrient-rich blood.

Conclusion

Using this systems biology approach, we identify metabolic shifts that arise with or in support of the resistant phenotype. This perspective allows us to more productively analyze and interpret clinical expression data for the identification of candidate drug targets for the treatment of resistant parasites.

Keywords

  • Plasmodium falciparum
  • Malaria
  • Metabolism
  • Network reconstruction
  • Artemisinin resistance
  • Flux balance analysis

Background

Three billion people are at risk for malaria infection globally and treatment approaches are failing. Malaria is caused by Plasmodium parasites, and most deaths are associated with human-infective P. falciparum. Without an efficacious vaccine, antimalarials are essential to combat the severity and spread of disease. Combination therapies are implemented to preserve antimalarial efficacy and slow resistance development [13]; despite this approach, this eukaryotic pathogen has developed resistance to every antimalarial on the market [46].

Typically, resistance is conferred by genomic changes that lead to drug export or impaired drug binding (for example [7]); however, non-genetic mechanisms have also been implicated in Plasmodium resistance development [810] and other pathogenic organisms, such as Pseudomonas aeruginosa [11] (reviewed in [12]). These laboratory-based studies provide insight into metabolic flexibility but the presence of relatively few examples limit our understanding of this method of adaptation, especially in malaria. Here, we aim to look beyond genetic mechanisms of resistance to identify resistance-associated metabolic adaptation. We hypothesize that metabolic changes must occur to support the resistance phenotype and resistance-conferring mutations. Ultimately, these changes, or ‘shifts,’ are required to increase the fitness of resistant parasites, or support the development of additional genetic changes that affect fitness. Metabolic or phenotypic ‘background’ could be as important as genetic background in the development of resistance.

In clinical malaria infections, artemisinin resistance is established in Southeast Asia [1315]. This phenotype is correlated with mutations in the P. falciparum Kelch13 gene [13, 14, 16, 17] and changes in both signalling pathways [1821] and organellar function [2229]. Overall, due to the complexity of artemisinin’s mechanism of killing (see citations above and [3036]), it has been challenging to separate the causes and effects of resistance. For this reason, there are few novel solutions to antimalarial resistance beyond altering the components of combination therapies to regain efficacy (e.g. artemisinin-atovaquone-proguanil [1]). We aim to gain a new perspective on resistance by viewing it through a ‘metabolic lens’. By characterizing the metabolic shifts that occur during or after resistance acquisition, we can begin to understand more about what it takes to support new functions, such as novel signalling (e.g. PI3K signalling is affected by PfKelch13 mutations [14, 15, 20, 37, 38]), drug detoxification (e.g. regulating ROS stress associated with artemisinin treatment [24, 25, 30, 33]), or stage alterations (e.g. dormancy of early ring stages [18, 3942]) in resistant parasites. Once we identify these compensatory changes, we can potentially target them. Plasmodium metabolic genes are better characterized than signalling pathways, as (for example) PlasmoDB identifies 43 3D7 genes associated with the term ‘signalling’ as opposed to 1112 3D7 genes associated with the term ‘metabolism’ [43], and many antimalarials target metabolic functions [4447]. Moreover, metabolism has been described as the best-understood cellular process [48], making interpreting metabolic analyses more tractable. Ultimately, if we can identify targetable conserved metabolic differences that arise with or in support of resistance, we can develop more robust antimalarial combination therapies aimed at preventing resistance.

Here, we use a systems biology approach to analyze the metabolic profile associated with resistant and sensitive parasites. First, to maximize the accuracy of our predictions, we curated an existing genome-scale network reconstruction of asexual blood-stage P. falciparum metabolism. Using constraint-based metabolic modeling, we integrated transcriptomic data from over 300 clinical isolates from Cambodia and Vietnam with varying levels of artemisinin sensitivity. This approach identified innate metabolic differences that arise with or in support of the resistant phenotype, despite large clinical variability, over multiple genetic backgrounds. Additionally, we were able to explore the functional consequences of expression changes by predicting essential enzymes within these distinct metabolic contexts; these enzymes are candidate drug targets for the prevention of drug resistance.

Results

Analysis of artemisinin sensitive and resistant transcriptomes

In order to investigate the presence of a distinct metabolic phenotype in artemisinin resistant parasites, we analysed a previously published expression dataset of clinical isolates from Southeast Asia (NCBI Gene Expression Omnibus accession: GSE59097). Patient blood samples were collected immediately prior to beginning artemisinin combination therapy, and their relative expression was evaluated via microarray [49]. This dataset profiles (1) in vivo artemisinin naïve parasites, providing a view of the innate differences between sensitive and resistance parasites, and (2) a diverse population of parasites collected from multiple collection sites across two countries, allowing us to summarize variable resistant phenotypes that laboratory adapted parasites and in vitro assays cannot practically encompass.

We confined our analysis of this previously published expression data to ring-stage parasites from Cambodia and Vietnam, two countries that had clear resistant and sensitive parasite populations as defined by parasite clearance half-life, an in vivo phenotypic measure of resistance, and PfKelch13 mutations, a commonly-used genetic marker of resistance (Fig. 1a & b). There were 97 and 24 ring-stage resistant parasite expression profiles from Cambodia and Vietnam, respectively; resistant parasites are defined by both the presence of PfKelch13 mutations and a parasite clearance half-life of more than 5 h. There were 141 and 43 ring-stage sensitive parasite expression profiles from Cambodia and Vietnam, respectively, as defined by wild-type PfKelch13 alleles and clearance half-life of less than 5 h. Despite obvious genotypic and phenotypic separation (Fig. 1a & b), artemisinin sensitive and resistant parasites do not separate well by hierarchical clustering of expression data (Fig. 1c).
Fig. 1
Fig. 1

Ring-stage parasites are genotypically and phenotypically distinct, yet expression profiles fail to separate resistance phenotypes. a & b Genotypic clustering: Genotypic (any mutation in PfKelch13) and phenotypic markers (parasite clearance half-life) were used to define artemisinin resistance in ring-stage parasites from GSE59097; using both markers, resistant and sensitive parasites from Cambodia (a) and Vietnam (b) separated into distinct populations. Genotype was identified in [49] with samples classified as containing the reference allele (blue), a mutant allele (red, any in the PfKelch13 propeller domain), a mixed population (black, at least two reads from each the reference and mutant alleles), or missing (grey, no sequencing data or fewer than 5 reads). c Phenotypic clustering: Resistant (red) and sensitive (blue) parasites from the two countries fail to cluster with consideration of genome-wide gene expression data (data not shown) or expression of metabolic genes alone

Additionally, when comparing sensitive parasites to resistant parasites in either country, the fold change of transcript expression is moderate; no genes exhibited notable differential expression across both analyses (fold change >2 or <0.5 for both Cambodia and Vietnam sample sets, data not shown). Among metabolic genes specifically, expression differences are small (maximum fold change 0.6 and 1.6) and few are both significant and conserved between data sets (11 in common from 174 in Cambodia and 37 in Vietnam; Additional file 1: Figure S1A & B). Large amounts of transcriptional variation (due to stage-dependent expression, genotypic variability, and host-pathogen interactions) across the population of clinical parasites may hide differences in the data sets. Moreover, we built a Random Forest classifier with expression data to predict resistance outcomes; the classifier predicted resistance poorly, with only 30.77% sensitivity (indicating only 30.77% of resistant samples were correctly identified) and 97.96% specificity (indicating 97.96% of sensitive samples were correctly identified) (Additional file 2: Figure S2A).

Although the expression data classifier performed poorly, a similar classifier built from metadata associated with each sample (patient and parasite characteristics) was highly predictive of resistance status with 85.71% sensitivity and 88.91% specificity (Additional file 2: Figure S2B). In our analysis, two specific mutations and collection site were the most predictive of resistance status; removing any of these three variables decreased classifier accuracy by over 20%. If Kelch13 mutations are used to predict resistance (rather than used to define resistance), Kelch13 mutations are most predicative of resistance (data not shown). Thus, metadata better predicts resistance than expression data. In order to deconvolve this innate variability and identify functional cellular changes associated with varying levels of artemisinin sensitivity, we integrated metabolic expression data into a genome-scale metabolic model of blood-stage P. falciparum.

Manual metabolic network curation

To maximize the predictive ability of the metabolic network model, we curated an existing, well-validated reconstruction of asexual blood-stage P. falciparum (iTH366, [50]) to improve its scope, and species- and stage-specificities. Our curated reconstruction, iPfal17, includes all metabolic reactions encoded by characterized genes in the parasite’s genome, summarizing metabolic behavior during the asexual blood-stage parasite. It is larger in scope from the previously published version due to the addition of 268 reactions (Table 1 , Additional file 3: Table S1 & S2), with 9.6% more enzymatic reactions and 2.3% more reactions with gene annotations. We also added 124 genes to the network (Table 1 & Additional file 3: Table S1). It is larger in scope and gene coverage than a recent de novo reconstruction (Table 1). iPfal17 has gene annotations for 80.0% of enzymatic reactions, and 20.5% of transport and exchange reactions (Fig. 2). iPfal17 includes 25.4% of the 1178 EC annotations in the P. falciparum genome, adding 14 EC numbers [43] (Additional file 3: Table S1). We evaluated enzyme complex or isozyme status and replaced 7 gene-protein-reaction relationships (Additional file 3: Table S1).
Table 1

Asexual blood-stage Plasmodium falciparum parasite model, iPfal17, summary statistics

 

iTH366 [50]

iPfa [71]

iPfal17

Reactions

1001

1066

1192

Enzymatic reactions

658

670

721

Reactions with gene annotations

657

586

672

Reactions with annotated citations

0

0

231

Metabolites

915

1258

991

Genes

366

325

482

Biomass components

51

73

82

Metabolites in extracellular environment

108

236

152

Fig. 2
Fig. 2

iPfal17 model curation is broad and comprehensive. Number of reactions in the P. falciparum reconstruction grouped by metabolic subsystems. Subsets of those reactions with gene annotations, literature citations, and modifications in the curation effort for this reconstruction are noted

Following curation, the species- and stage-specificity of the model was also improved. Gene annotations were evaluated against PlasmoDB resources [43], resulting in 124 additional gene annotations (Additional file 3: Table S1). Importantly, we removed cellular import of pyrimidines from the host erythrocyte, as P. falciparum relies on de novo synthesis (Additional file 3: Table S2) [47, 51]. Blood-stage specificity was improved by removing genes only used in other life stages (specifically, the gene encoding chitinase [52]). Additionally, 77 functionally unnecessary reactions were removed due to a lack of genetic and biochemical support (Additional file 3: Table S2). Reactions necessary for growth were added manually (Additional file 3: Table S1). Reactions were individually curated, changing metabolite utilization and stoichiometry (Additional file 3: Table S1).

The iPfal17 reconstruction contains five compartments: extracellular space and four intracellular compartments (cytoplasmic, mitochondrial, apicoplast, and food vacuole, Additional file 3: Table S1). Few studies since the Plata, et al. reconstruction (iTH366) investigated protein localization and therefore, few changes were made to compartmental assignments; the food vacuole compartment, containing two reactions, was added in this version of the reconstruction (Additional file 3: Table S1). As in iTH366, reactions with unknown localization were placed within the cytoplasm (Additional file 3: Table S1) [53]. Again, similar to iTH366, a mitochondrial inner matrix was not added, as there is no evidence that the blood-stage parasite requires a proton gradient for energy production [51, 54, 55]. Nonpolar metabolites generated in one compartment and utilized in another were transported as needed for network functionality by assuming passive diffusion [53].

We also included annotations that will accelerate future curation efforts. First, we did not remove blocked reactions (those that do not carry flux due to their lack of connectivity to other components of the network) because further research may add connectivity to these network components. iPfal17 contains 303 blocked reactions and 78 dead-end metabolites (specifically, 32 metabolites are not consumed and 46 are not produced). For example, 4-pyridoxate (a byproduct of vitamin B6 biosynthesis) is included; production is supported by bioinformatic analyses of the parasite genome, but the metabolite function or excretion pathway is not known. Second, citations are included within iPfal17 to identify the date of discovery and degree of literature support for each reaction (Additional file 3: Table S1 & S2). Literature support was only added to modified reactions, resulting in 231 citations (Table 1 & Additional file 3: Table S1).

Metabolomics curation of biomass reaction

For the newly curated iPfal17 model, we modified the Plasmodium biomass reaction to better represent in vitro data (Table 2). We added tRNA-ligated amino acids to the amino acid requirements to force protein production, rather than only demanding free amino acids. Additionally, lipid classes were added based on recently published metabolomics findings; phosphatidylinositol, phosphatidylglycerol, sphingomyelin, diacylglycerides, and triglycerides were added due to their observed increase in abundance between uninfected and infected erythrocytes [56]. Phosphatidylcholine ethers, acyl phosphatidylgycerol, lysophosphatidylinositol, bis(monoacyl-glyceryl)phosphate, and monosialodihexosylganglioside were excluded from the biomass reaction, as there is no known Plasmodium catabolism or import pathways for these lipids [56]. Analysis of metabolomics data enabled further curation of the biomass reaction with the addition of malate, alpha-ketoglutarate, and glutathione (both reduced and oxidized) [28, 57, 58]. Importantly, we included the requirement for cellular export of lactate and hemozoin. Lactate is measured in extracellular in vitro metabolomics and in vivo via blood acidosis; it is the terminal product of glycolysis, the sole energy production pathway used by the blood-stage parasite [5962]. By requiring lactate export, we force the model to utilize glycolytic energy metabolism. Similarly, hemoglobin degradation is essential for the blood-stage parasite to produce free amino acids. Parasites can also import and synthesize some amino acids, but the breakdown of hemoglobin (and subsequent production of its byproduct, hemozoin) is necessary for growth [23, 63, 64]. Thus, by requiring hemozoin export, we force the in silico parasite to degrade hemoglobin as the primary pathway for amino acid production.
Table 2

Metabolic components of the biomass function

Complex metabolites

• protein, composed of:

 ◦ tRNA ligated amino acids (20)*

• lipid, composed of

 ◦ sphingomyelin*

 ◦ cholesterol

 ◦ phosphatidyl choline

 ◦ phosphatidyl ethanoloamine

 ◦ triacylglycerides*

 ◦ diacyclglycerides*

 ◦ phosphatidyl inositol*

 ◦ phosphatidyl glycerol*

 ◦ acyl phosphatidyl glycerol*

• reduced and oxidized glutathione*

• protoheme

Amino Acids

• alanine

• arginine

• asparagine

• aspartate

• cysteine

• glutamate

• glutamine

• glycine

• histidine

• isoleucine

• leucine

• lysine

• methionine

• serine

• phenylalanine

• proline

• threonine

• tryptophan

• tyrosine

• valine

Carbohydrates

• malate*

• α-ketoglutarate*

Nucleotides

• ATP

• dATP

• CTP

• dCTP

• GTP

• dGTP

• UTP

• dTTP

• thiamine diphosphate

Excreted metabolites

• lactate*

• hemozoin*

Vitamins

• pyridoxal

• 5-phosphate riboflavin

Other

• s-adenosyl l-methionine

• putrescine

• spermidine

• 2-octaprenyl 6-hydroyphenol

• f-thf

• mthf

• thf

• FAD

• coenzyme-A

• NAD

• water

• Fe2+ & Fe3+

• NADP

• SO4

• NH4+

f-thf = formyl tetrahydrofolate; mthf = methyltetrahydrofolate; thf = tetrahydrofolate

*metabolites that have been added to the iPfal17 and are not present in the biomass function of iTH266

iPfal17 validation and functional requirements

To validate the model against experimental results, essential metabolic tasks of blood-stage growth were identified and evaluated (Table 3). These tasks simulate experimental manipulations of the parasite or culturing environment, or clinical observations. For example, the parasite is able to grow with glucose as the sole carbon source and hypoxanthine as the purine source, and the parasite’s induction of blood acidosis via lactate [6567]. Additional tasks include the parasite’s failure to grow in the presence of antimetabolites for riboflavin, nicotinamide, thiamine, and pyridoxine [68]. We defined this set of tasks to provide a framework for curation and validation efforts of future network reconstructions. Although iPfal17 fails to pass all metabolic task simulations, we believe this is the most comprehensive and accurate model to date due to the curation efforts and results from tests of the metabolic tasks. Failures generally exist in pathways that currently contain many reversible reactions (i.e. tasks 5a–b for glycolysis) or if the experimental evidence is not mechanistic (i.e. tasks 1a–d) or fully characterized (i.e. task 4; Table 3).
Table 3

Experimentally derived metabolic tasks for evaluating iPfal17

 

Metabolic Task

In vitro

iPfal17

Hypothesis for in vitro/in silico discrepancies

1a

Growth in the presence of antimetabolite, riboflavin?

no [68]

no

-

1b

Growth in the presence of antimetabolite, thiamine?

no [68]

yes

Unknown antimetabolite mechanism; Off target effects of antimetabolite

1c

Growth in the presence of antimetabolite, nicotinamide?

no [68]

yes

Unknown antimetabolite mechanism; Off target effects of antimetabolite

1d

Growth in the presence of antimetabolite, pyridoxine?

no [68]

yes

Unknown antimetabolite mechanism; Off target effects of antimetabolite

2a

Grows without loops?

no

no

-

2b

ATP production if no exchange is allowed?

no

no

-

3a

Can produce purines?

yes

yes

-

3b

Growth with hypoxanthine as the only purine source?

yes [65]

yes

-

3c

No growth if guanine, guanosine, inosine, adenine, or adenosine are only purine sources?

yes [65]

60%

-

4

Growth with IPP supplementation and no apicoplast?

yes [139]

no

Nuclear encoded proteins that function within the apicoplast may be expressed in the cytoplasm if the organelle is not present.

5a

Growth with glucose?

yes [66]

yes

-

5b

Growth with alternative sugar source (no glucose, with ribose, mannose, fructose, galactose, or maltose)?

no [66]

yes

Central carbon metabolism contains many reversible reactions. Carbon sources that support growth are debated [140].

6a

Can produce all amino acids except isoleucine?

yes [66]

yes

-

6b

Is growth reduced without methionine, proline, tyrosine, cystine, glutamate, or glutamine supplementation?

yes [63]

no

Model is not designed for growth reduction experiments.

6c

Growth without isoleucine supplementation?

no [63, 93]

no

-

7

Growth without calcium pantothenate?

no [93]

no

-

8

Growth without p-aminobenzoic acid?

no [141]

no

-

9

Cannot produce any metabolites if no exchange is allowed?

no

no

-

10

Accuracy of experimental essentiality predictions

-

79.5%a

See Table 4 and Additional file 3: Table S7

11

Accuracy of P. berghei essentiality predictions

-

61.4%a

See Additional file 3: Table S6

aAccuracy calculated as the sum of true positives and true negatives, divided by total observations

We also evaluated predictions of the effects of gene knockouts and enzyme inhibitors using previously published experimental results (Table 4; Additional file 3: Table S7). Our updated model had improved accuracy of gene and reaction essentiality predictions, compared to previous models (Table 4). We predict that there are 159 essential reactions, and 107 lethal single gene knockouts (Additional file 3: Table S3 & S4). Of experimentally validated knockouts, iPfal17 accurately predicts essentiality of 79.5% of genes and enzymes tested in P. falciparum and 61.4% for those tested in P. berghei (Tables 3 & 4 , Additional file 3: Table S6); predictions are also more accurate for gene knockouts and are less accurate in predicting enzyme inhibition (Tables 3 & 4).
Table 4

Knockout predictions with experimental validation

Enzyme

Gene

In vitro

In vitro method

Species

Citation

iTH366

iPfal17

Dihydrofolate reductase; thymidylate synthase

PFD0830w

L

Inhibitor (1843 U89)

Pf

[142]

L

L

FABI, enoyl-acyl carrier reductase

PFF0730c

1) L

2) NL

1) Inhibitor (Triclosan)a 2) Gene KO; siRNA

1) Pf

2) Pb

1) [99]

2) [143, 144]

-

NL

FABB/F 3-oxoacyl-acyl-carrier protein synthase I/II

PFF1275c

1) L

2) NL

1) Inhibitor (Cerulenin)

2) Gene KO

1) Pf

2) Pb

1) [99]

2) [144]

-

NL

Dihydroorotate dehydrogenase

PFF0160c

L

RNAi; Inhibitors (several)

Pf

[145, 146]

L

L

Adenosine deaminase

PF10_0289

L

Inhibitor (methylthiocoformycin)

Pf

[102]

Lb c

cKO: NL

Deoxyuridine 5-triphosphate nucleotido- hydrolase

PF11_0282

L

Inhibitors (several)

Pf

[147]

NL

L

Lactoyl glutathione lyase

PF11_0145 PFF0230c

L

Inhibitor (S-p-bromobenzylglutathione diethyl ester)

Pf

[148]

NL

NL

Sphingomyelinase

PFL1870c

L

Inhibitor (Scyphostatin)

Pf

[149]

NL

NL (GR)

Plasmepsin II

PF14_0077

L

Inhibitors (several)

Pf

[150]

-

NL

Cytosolic lysyl-tRNA synthetase

PF13_0262

L

Inhibitor (cladosporin)

Pf

[151]

-

L

Gamma-Glutamylcysteine synthase

PFI0925w

1) L

2) NL

1) Inhibitor (L-buthionine sulfoximine); fail to Gene KO

2) Gene KO

1) Pf

2) Pb

1) [152]

2) [27]

-

NL

Glutathion s-transferase

PF3D7_ 1419300

L

Inhibitors (ellagic acid, others)

Pf

[153]

-

NL

Glutathione reductase

PF3D7_ 1419800

1) L

2) NL

1) Inhibitors (several); fail to KO

2) Gene KO

1) Pf

2) Pb

1) [154, 155]

2) [156]

-

NL

5-Aminolevulinic acid synthase

PF3D7_ 1246100

1) NL

2) L

1) Gene KO

2) Inhibitor (Succinyl acetone)

1) Pf, Pb

2) Pf

1) [100, 101]

2) [99]

L

NL

Aconitase

PF13_0229

NL

Gene KO; Inhibitor (Sodium fluoroacetate)

Pf

[60, 61]

-

NL

α-Ketoglutarate dehydrogenase

PF3D7_ 0820700

NL

Gene KO

Pf

[60]

-

NL

Succinyl-CoA synthetase

PF3D7_ 1108500

NL

Gene KO

Pf

[60]

-

NL

Protoporphyrinoxygen oxidase

PF10_0275

L

Inhibitor (Acifluorfen)

Pf

[99]

L

NL

Predictions for 18 enzymes of interest are included here. See Additional file 3: Table S7 for the complete list of predictions

Italics, inconsistent with experimental results; Bold, conflicting experimental results; Tg, Toxoplasma gondii; Pf, Plasmodium falciparum; Pb, Plasmodium berghei; a, known off target effects; b, modified media conditions; c, contrary to published; KO, knockout; cKO, conditional KO; GR, growth reducing; L, lethal; NL, nonlethal

Integration of expression data into the metabolic model

With this high-quality metabolic network reconstruction, we integrated expression data from sensitive and resistant parasites collected in Cambodia and Vietnam into iPfal17 using the Metabolic Adjustment for Differential Expression algorithm (MADE [69]). MADE constrains gene utilization in the model to maximally account for statistically significant changes in expression while maintaining network functionality requirements (e.g. parasite viability). MADE integrates differential expression by minimizing the difference between significant expression changes (up/down) and model constraints (gene usage); this avoids arbitrary thresholding and ensures the condition-specific model is consistent with experimental data. Essential genes and genes supported by expression data (by having no change in expression or being upregulated in that condition) remain in the model that represents that condition. Conversely, if a gene is significantly down regulated in a condition and not functionally necessary for metabolism, the reactions catalyzed by the encoded enzyme will be removed from the model. Therefore, condition-specific models contain a reduced network with a subset of reactions annotated in the original curated reconstruction that are either necessary for network functionality (as defined by the objective function) and/or are supported by expression data [69]. Thus, MADE generates functional condition-specific models representing the cell’s metabolic capability given the condition-specific expression.

MADE integration of sensitive and resistant expression data from both countries generated four condition-specific models (Fig. 3). By comparing these models, we identified differences in gene and pathway utilization between resistant and sensitive parasites that are consistent between the isolates from the two countries (Additional file 4: Fig. S3). First, we conducted an enrichment analysis on genes that remain in (i.e. can be utilized by) each constrained model by comparing to the unconstrained curated model. As expected, all four models were enriched with genes involved in pathways with many essential reactions or little redundancy, such as transport reactions, tRNA synthesis, purine metabolism, and others (Additional file 5: Fig. S4, see model). Sensitive (wild type) models corresponding to isolates from both Cambodia and Vietnam are uniquely enriched with the utilization of genes involved in the metabolism of nicotinate/nicotinamide (p-value = 1.47*10−2), glutamate (p-value = 1.28*10−13), and selenocysteine (p-value = 5.85*10−4). Thus, sensitive models contain more reactions in these pathways than the unconstrained model, resulting from increased expression of these pathways in sensitive parasites (Additional file 5: Fig. S4). Resistant models from both countries are uniquely enriched with the utilization of genes involved in pyrimidine (p-value = 2.18*10−7), polyamine (p-value = 4.39*10−4), redox reactions (p-value = 5.13*10−5), and central carbon metabolism (glycolysis [p-value = 4.39*10−4] and the pentose phosphate pathway [p-value = 6.06*10−3]). Thus, resistant models have a larger proportion of their total reactions associated with these pathways than the original unconstrained model, whereas sensitive models do not have this enrichment. This indicates that these pathways are upregulated in resistant parasites and may remain important for metabolism in the resistant state (Additional file 5: Fig. S4).
Fig. 3
Fig. 3

Computational pipeline. We curated an existing blood-stage P. falciparum reconstruction to generate our iPfal17 network reconstruction. We integrated transcriptomics data into this model using the MADE algorithm to generate four condition-specific models. We used these models to predict reaction essentiality; we highlight consensus results across resistant or sensitive models. MADE, Metabolic Adjustment for Differential Expression

Identification of conserved and uniquely essential pathways

Beyond general differences in pathway utilization, which encompasses both essentiality and pathway-level differences in expression, artemisinin sensitive and resistant parasites have unique essential genes and reactions. To identify these essential reactions and provide insight on targetable metabolic enzymes in the clinical isolates, we performed in silico single gene and reaction deletions with each of the four condition-specific models. Datasets from the parasites from each country were initially analyzed separately and then lists were compared to ensure resistance-associated trends are reproducible and observed in independent analyses. As expected, we identified many essential functions conserved in all models (Additional file 3: Table S5), which is consistent with an active core metabolism required for basic parasite survival. Importantly, 21 reactions were essential in only resistant models, but not sensitive models (Table 5). Theoretically, drugs targeting these reactions would kill resistant parasites and have no effect on sensitive parasites; thus, there would be no selective pressure within the sensitive parasite population to develop resistance to these drugs. This list included serine hydroxymethyltransferase (PFL1720w in folate metabolism), the glycine cleavage system (PFL1550w and others in folate metabolism), thiamine diphosphokinase (PFI1195c in cofactor metabolism, specifically thiamine diphosphate), fumarate hydratase and malate dehydrogenase (PFI1340W and PFF0895w, respectively, in the mitochondrial electron transport chain and TCA cycle), and fructose hexokinase (PFF1155W in glycolysis; Table 5). We also identified 12 reactions that were essential only in artemisinin sensitive parasites (Table 6). Drugs targeting these reactions should not be combined with artemisinin, as they would not kill (and may select for) resistant parasites. Fortunately, no existing drug targets were found in this list of essential genes and reactions (Table 6). Among those identified were sphingomyelin synthase 2 (PFF1215w) and several transport reactions, which furthers our understanding of condition-specific intra-organellar function (Tables 5 & 6). Overall, our systems biology-based approach reveals unique metabolic phenotypes associated with artemisinin sensitivity; these differences were not detected in the original analysis of the expression dataset or by separately analyzing Cambodian or Vietnamese isolates ([49] and data not shown).
Table 5

Essential reactions unique to resistant parasites

Reaction

Reaction Formula

EC Number

Reaction Function

Genes

CO2tmt

CO2[m] < => CO2[c]

-

CO2 transport

-

EX_folate4

p-aminobenzoate[e] < =>

-

p-aminobenzoate exchange

-

EX_fru(e)

fructose[e] < =>

-

fructose exchange

-

EX_thm(e)

thiamine[e] < =>

-

thiamine exchange

-

FRUt1r

fructose[e] < => fructose[c]

-

fructose transport

PFB0210c

FUM_mt

fumarate [m] + H2O[m] < => malate[m]

4.2.1.2

fumarate hydratase in the TCA cycle

PFI1340w

FUMtmt

fumarate[m] < => fumarate [c]

-

fumarate transport into mitochondria

-

GHMT2r

serine[c] + thf[c] < => glyine[c] + H2O[c] + mthf[c]

2.1.2.1

serine hydroxymethyltransferase in folate synthesis

PFL1720w

GLYCL_mt

glycine[m] + NAD[m] + thf[m] < => CO2[m] + mlthf[m] + NADH[m] + NH4[m]

many

glycine cleavage system in folate synthesis and amino acid metabolism

PF13_0345a

PFL1550w

MAL13P1.390

PF14_0497

PF11_0339

GLYtmt

glycine[m] < => glycine[c]

-

glycine transport into mitochondria

-

HEX7

ATP[c] + fructose[c] = > ADP[c] + fructose-6-phosphate[c] + h[c]

2.7.1.1

hexokinase of glycolysis

PFF1155w

MDHm

malate[m] + NAD[m] < => h[m] + NADH[m] + oxaloacetate[m]

1.1.1.37

malate dehydrogenase in the TCA Cycle

PFF0895w

MLTHFtmt

mthf[m] < => mthf[c]

-

mthf transport into mitochondria

MAL8P1_13*

PF11_0172

NADPHtmt

NADPH[c] < => NADPH[m]

-

NADPH transport into mitochondria

-

NADPtmt

NADPc] < => NADP[m]

-

NADP transport into mitochondria

-

NH4tmt

NH4[m] < => NH4[c]

-

NH4 transport into mitochondria

-

OAAtmt

oxaloacetate [m] < => oxaloacetate[c]

-

oxaloacetate into mitochondria

-

THFtmt

thf[m] < => thf[c]

-

thf into mitochondria

-

THMt3

h[c] + thiamine[e] < => h[e] + thiamine[c]

-

thiamine import

-

TMDPK

ATP[c] + thiamine[c] = > AMP[c] + h[c] + thiamine diphosphate[c]

2.7.6.2

thiamine diphosphokinase in cofactor metabolism

PFI1195c

pABAt

p-aminobenzoate[e] < => p-aminobenzoate[c]

-

p-aminobenzoate import

MAL8P1_13a PF11_0172

All reactions in table are predicted to be lethal when removed from both Cambodia and Vietnam resistant models

a, deleted from at least one resistant model due to expression constraints by MADE localization: [e] extracellular, [c] cytoplasmic, [m] mitochondria, [ap] apicoplast

Table 6

Essential reactions unique to sensitive parasites

Reaction

Reaction Formula

EC Number

Reaction Function

Genes

2_7_8_3

CDP-choline[c] + ceramide[c] + h[c] = > CMP[c] + sphingomyelin[c]

2.7.8.3

sphingomyelinase 2 in lipid metabolism

PFF1210wa

PFF1215w

AMETt2

adenosyl methionine[e] + h[e] = > adenosyl methionine[c] + h[c]

-

adenosyl methionine import

PF11_0334

PFB0435ca

PFE0775ca

PFF1430c

PFL0420w

PFL1515ca

EX_o2(e)

O2[e] < =>

-

oxygen exchange

-

EX_ptrc(e)

putrescine[e] < =>

-

putrescine exchange

-

GAT_c

diacylglycerol[c] + acyl-coenzyme-A[c] = > coenzyme-A[c] + triacylglycerol[c]

2.3.1.20

diacylglycerol O-acyltransferase in lipid metabolism

PFC0995c

GPDDA4

glycerophosphoglycerol [c] + H2O [c] = > glycerol 3-phosphate[c] + glycerol[c] + h[c]

3.1.4.46

glycerophosphodiester phosphodiesterase in lipid metabolism and glycolysis

PF14_0060

O2t

O2[e] < => O2[c]

-

oxygen import

-

O2tmt

O2[m] < => O2[c]

-

oxygen transport into mitochondria

-

PItap

phosphate[ap] < => phosphate[c]

-

phosphate transport into apicoplast

-

PTRCt2

h[e] + putrescine[e] = > h[c] + putrescine[c]

-

putrescine import

-

PYK

ADP [c] + h[c] + phosphoenol pyruvate[c] = > ATP[c] + pyruvate[c]

2.7.1.40

pyruvate kinase in glycolysis

PFF1300w

amet_ex

adenosyl methionine[e] < =>

-

adenosyl methionine exchange

-

All reactions in table are predicted to be lethal when removed from both Cambodia and Vietnam sensitive models

a, deleted from at least one sensitive model due to expression constraints by MADE localization: [e] extracellular, [c] cytoplasmic, [m] mitochondria, [ap] apicoplast

Discussion

Systems biology approaches enable unbiased analyses of antimalarial resistance phenotypes. Here, we describe a newly curated metabolic network reconstruction of the malaria parasite that can serve as a platform for the analysis of gene expression and other ‘omics data, and as a tool to generate testable hypotheses regarding essential genes and metabolic phenotypes. In particular, we used this network reconstruction to characterize key metabolic dependencies in resistant and sensitive parasites. We revealed emergent patterns in pathway activity, differential utilization of organelles, metabolic flexibility, and targetable weakness of resistant parasites.

Data-driven model curation improves predictive capability

Several P. falciparum reconstructions have been generated since the publication of iTH366, including those highlighting unique developmental stages within the blood-stage asexual cycle by integrating stage-specific expression [70], de novo reconstructions to implement novel modeling approaches [71], integrated host and pathogen networks [72], and those exploring the other life stages of the parasite [73, 74]. iPfal17 represents the most comprehensive and validated metabolic reconstruction of the asexual blood-stage malaria parasite, P. falciparum, to date. With iPfal17, we can simulate growth and predict gene and reaction essentiality and integrate datasets to probe targeted phenotypes, like resistance. It is larger in scope than previous models, includes more gene annotations, and documents literature citations associated with its components (Table 1 & Additional file 3: Table S1, Fig. 2). Moreover, invalid reactions have been removed, improving accuracy (Additional file 3: Table S2). These curation efforts improve the model validity by better recapitulating experimental results, removing functions known to not occur in the asexual blood-stage parasite, and adding functions for which there is experimental evidence. Thus, gene and reaction knockout predictions generated with this model are more accurate. Moreover, iPfal17 has greater interpretability as reaction citations are included and accessible to users.

iPfal17 is similar in functional distribution and scope to other high quality models of apicomplexans, despite its reduced genome size. The P. falciparum genome is 23.3 MB and contains 5423 genes (excluding the antigenic var. genes) [43, 75, 76]; iPfal17 accounts for the function of 987 metabolites, 730 enzymatic reactions, 1195 total reactions, and 488 genes (Table 1). For reference, the network reconstruction for Toxoplasma gondii, with a genome of 80 MB with 8000 genes [77, 78], accounts for 1019 metabolites, 1089 enzymatic reactions, 3387 total reactions, and 527 genes [79]; with a genome of 32.8 MB and 8272 genes [80], the Leishmania major network reconstruction accounts for 1101 metabolites, 1047 enzymatic reactions, 1112 total reactions, and 560 genes [81]. These parasites all have notably poor genome annotation (40–60% of the genes are unknown) [43, 75] and, thus, have fewer associated genes than many other reconstructions (e.g. the E. coli and S. cerevisiae reconstructions account for 1366 and 910 genes [82], respectively [82, 83]).

Intracellular parasites, like Plasmodium, require more exchange and transport reactions as they obtain many nutrients from the host environment [57, 8487]. This reliance on the host for metabolic function permits the parasite to increase fitness by reducing its genome and hijacking host function. P. falciparum does just that: the parasite remodels the host erythrocyte, generating a vesicular network for protein translocation and increasing host cell permeability for nutrient acquisition from the host serum [8892]. Thus, the apicomplexan network reconstructions include more transport reactions, many of which are not genetically mapped. Additionally, we chose to exclude an erythrocytic host compartment from the extracellular environment, despite the parasite’s intra-host growth [57, 66, 68, 93]. Other recent reconstructions [72, 94] have added this compartment, but the erythrocytic compartment is unlikely to improve model function due to the gross disruption of the host membrane as a barrier [57, 66, 68, 93].

We generated gene and reaction essentiality predictions with our curated network model, prior to integration of expression data, and found results largely consistent with previous models [50] (Table 4). We identified 159 essential reactions and 107 essential metabolic genes (Additional file 3: Table S3 & S4); 24 of these have been empirically tested in cultured P. falciparum parasites (Table 4 , and in P. berghei- Additional file 3: Table S6). iPfal17 better predicts experimentally determined essential reactions than previous models, across a broad set of metabolic pathways (Table 4 and data not shown). iPfal17 predictions fail when essential genes or reactions are involved closely with spontaneous reactions (i.e. lactoylglutathione lyase is downstream of a spontaneous reaction and upstream of nonmetabolic redox products), are in pathways with uncharacterized mechanisms (i.e. plasmepsin II in hemoglobin degradation) or if experimental evidence is contradictory (i.e. heme biosynthesis pathway; Table 4).

Because pharmacological enzyme inhibition can be quite noisy and genetic modification has been challenging in Plasmodium, the development of CRISPR-Cas9 and other technologies will make it possible to integrate new experimental observations into the model with increasing accuracy [9598]. Until then, the model can be used to identify enzyme inhibitors with off-target effects. For example, within the heme biosynthesis pathway, pharmacological inhibition of aminolevulinic acid dehydrogenase and protoporphyrinogen oxidase kills blood-stage parasites [99]; however, disrupting the genes encoding the first (aminolevulinic acid dehydrogenase) and last (ferrochetalase) genes is not lethal in blood-stage parasites [100, 101]. iPfal17 predictions are consistent with the gene knockout experiments in P. falciparum of Ke, et al., suggesting that the enzyme inhibitors used by Ramya, et al. have off target effects (Table 4 and Additional file 3: Table S7). iPfal17 also fails to predict the lethal nature of adenosine deaminase in purine-free conditions [102]. Adenosine deaminase converts adenosine to hypoxanthine; as 38 reactions produce AMP, which then generate hypoxanthine products, we propose adenosine deaminase may be essential for nonmetabolic functions or the inhibitor of adenosine deaminase has off - target effects. Furthermore, these results generate hypotheses about the differential metabolic capabilities of P. falciparum and P. berghei, as experimental results in the rodent parasite conflict with some P. falciparum predictions (Tables 3 & 4 , Additional file 3: Table S6).

Data integration reveals distinct metabolic patterns

The integration of expression data from clinical parasites into our network reconstruction highlights the differential utilization of metabolic genes and reveals metabolic shifts associated with variation in innate artemisinin sensitivity (Additional file 4: Figure S3 & Additional file 5: Figure S4). Enriched metabolic pathways detected in sensitive and resistant models are consistent with previous experimental observations. For example, resistant models are uniquely enriched with genes involved in pyrimidine biosynthesis and mitochondrial redox reactions. This finding is consistent with the importance of mitochondrial function in surviving artemisinin stress [26, 29] and the physical interactions between artemisinin and proteins involved in glycolysis, nucleotide synthesis, and the mitochondria in mammalian cells and P. falciparum [103105]. Additionally, the metabolic disruption of the redox reactions in the electron transport chain upon artemisinin treatment (via decreased production of orotate and fumarate, presumably via dihydroorotate dehydrogenase and succinate dehydrogenase enzymes [22, 28, 106]) suggests that changes in these pathways may be important for survival in the presence of the drug. Thus, this metabolic network analysis approach allows us to filter out noise from diverse clinical isolates to identify alternative utilization of pathways associated with artemisinin resistance. However, due to the nature of this type of analysis, these enrichment results do not implicate specific reactions that are uniquely active in artemisinin sensitive or resistant parasites.

Condition-specific models have unique metabolic requirements

Upon integration of expression data and the identification of differentially utilized pathways above, we next used these models to predict targetable differences in sensitive and resistant parasites by identifying reactions that are essential within the context of the metabolic network (Additional file 3: Table S5, Tables 5 & 6). We identified (1) differences in intra-organellar function, (2) metabolic flexibility of scavenging and biosynthesis pathways, and (3) targetable weakness of resistant parasites. These metabolic shifts primarily reside in mitochondrial metabolism, as well as folate and polyamine metabolism. Together, these results highlight the overall plasticity of P. falciparum metabolism and opportunities for further development of potential drug targets.

Interestingly, several transport reactions are found to be differentially essential in our constrained models (Tables 5 & 6). Many transport reactions (79.5%) have no associated gene due to the incomplete characterization of the P. falciparum genome (Fig. 2). They are included in the model due to biochemical evidence or functional necessity (i.e. a metabolite is produced in one compartment but it is a substrate for an enzyme in another). Transcriptomic data integration does not constrain their behavior explicitly: expression integration reduces the total number of reactions in a model, forcing transport of metabolites among organelles if within-compartment biosynthesis is non-functional. Function within organelles requires transport and loss of function reduces transport needs. Specifically, several mitochondrial and apicoplast transport reactions are uniquely essential in the sensitive and resistant parasite populations (Fig. 4). In resistant models, this includes the mitochondrial transport of metabolites associated with the TCA cycle and electron transport chain (fumarate, oxaloacetate, and NADPH) and those involved in generation of folates (tetrahydrofolate, glycine, CO2, and NH4+) (Fig. 4a). In sensitive models, apicoplast transport of ADP, ATP, and phosphate is essential (Fig. 4a). Overall, these results indicate that sensitive and resistant parasites are differentially utilizing pathways within these organelles, and have unique requirements for transport of essential substrates. This observation is consistent with previous studies and our enrichment results highlighting the influence of mitochondrial metabolism on survival in the presence of artemisinin [26, 29]. Moreover, oxygen transport into the cell and then into the mitochondria is only essential in sensitive parasites, further predicting differential use of the mitochondria in these parasites as oxygen serves as the terminal step in the electron transport chain. Resistant parasites are predicted to generate oxygen within the mitochondria via superoxide dismutase as opposed to transport (Fig. 4a).
Fig. 4
Fig. 4

Artemisinin resistant and sensitive parasites have unique metabolite transport capabilities. a Transport differences: Resistant parasites exhibit greater metabolic flexibility, allowing either import or biosynthesis of putrescine, p-aminobenzoate, adenosyl-methionine into the parasite’s cytoplasm (grey). Sensitive parasites rely on import only Import or synthesis of ATP, ADP, and phosphate into the apicoplast (green organelle) is essential for sensitive parasites. Resistant parasites require transport of oxygen, fumarate, oxaloacetate, NADP, NADPH, tetrahydrofolate (thf), NH4, and glycine into the mitochondria, in yellow. b p-aminobenzoate in glycolysis: Resistant parasites generate p-aminobenzoate via alternative components of the glycolysis pathway. Arrows colored for flux via FVA and stars for essentiality. FVA, flux variability analysis

We also identify differential utilization of transport pathways from the extracellular environment into the parasite. Plasmodium metabolism contains redundancies; for many essential metabolites, the parasite’s genome encodes one or more biosynthetic pathways, while there is also evidence for a parallel host-scavenging pathway [91] (e.g. lipid [56] and amino acid [56, 63] scavenging). Upon model integration, we find that artemisinin resistant and sensitive parasites utilize some of these metabolic pathways in alternative ways (Fig. 4a). Bioinformatic analyses indicate Plasmodium can either scavenge or synthesize putrescine [43] and adenosylmethionine [43] (two essential polyamines and precursors to spermidine [50, 107]). Similar redundancy has been identified for the acquisition of p-aminobenzoate, a folate precursor generated by branch of glycolysis necessary for nucleotide synthesis ([43, 108]; Fig. 4a&b, Tables 5 & 6). These metabolites are measurable via blood sample metabolomics [108, 109]; therefore, host scavenging is a viable option for blood-stage parasites. We predict that sensitive parasites rely on the import of putrescine, adenosylmethionine, and p-aminobenzoate. Resistant parasite expression supports either host scavenging or direct biosynthesis due to parasite survival upon reaction knockout in silico. Thus, we expect that resistant parasites are more metabolically flexible for these metabolites; perhaps resistant parasites have failed to appropriately modulate their transition to the nutrient-rich blood-stage environment, and this unexpected flexibility is evolutionarily beneficial once confronted with artemisinin treatment.

Interestingly, recent metabolomics studies demonstrate that intra-parasitic putrescine levels are decreased upon artemisinin treatment [106]. Furthermore, protein interaction studies indicate artemisinin covalently binds with spermidine synthase and adenosylmethionine synthetase [110]. Activity in both the biosynthetic and scavenging pathway of putrescine and adenosylmethionine may allow resistant parasites to compensate for artemisinin’s effect on polyamines. The essential role of polyamines is well established in Plasmodium [111, 112]. In other organisms, these compounds stabilize DNA and RNA [113] and signal a pause in the cell cycle [114]. In the presence of artemisinin, perhaps polyamines act to stabilize the genome from oxidative stress [24, 30, 33] and trigger dormancy [18, 19]. As resistant parasites are more likely to survive dormancy, flexibility in polyamine metabolism could provide more routes for artemisinin survival [29, 115].

Our systems biology approach also identifies metabolic weaknesses of resistant parasites; these weaknesses can be used to identify drug targets for combination therapies (Fig. 5). For example, we identified the mitochondrial import of fumarate and subsequent conversion to oxaloacetate (via fumarate hydratase, PFI1340W, and malate dehydrogenase, PFF0895W) to be uniquely essential in resistant parasites (Fig. 5a, Table 5). Expression data from sensitive parasites supports mitochondrial import of malate and utilization of malate:quinone oxidoreductase (PFF0815W) to generate oxaloacetate from malate, bypassing the need for fumarate and the associated enzymes, fumarate hydratase and malate dehydrogenase. We predict that inhibitors of fumarate transport or fumarate hydratase and malate dehydrogenase would specifically kill artemisinin resistant parasites, offering an example of enhanced metabolic flexibility of sensitive parasites and a potential artemisinin-combination therapy target. The TCA cycle is essential during the mosquito-stage of parasite development [61, 116], but not the blood-stage [60, 61]; this once again highlights the possibility that resistant parasites exhibit incomplete transition to the metabolic state most appropriate for nutrient-rich blood.
Fig. 5
Fig. 5

Artemisinin resistance displays unique metabolic weaknesses. a Trycarboxylic acid cycle: Resistant parasites rely on generation of oxaloacetate from the conversion of fumarate to malate, using fumarate hydratase and malate dehydrogenase, in the mitochondria. Sensitive parasites can also import malate into the mitochondria and use an alternative enzyme (malate:quinone oxidoreductase) to convert malate to oxaloacetate. b Folate metabolism: Inhibition of the SHMT enzyme (left) and the glycine cleavage system (right) is lethal in resistant parasites. Sensitive parasites can use either of these enzyme complexes interchangeably to produce mthf and thf. c Cofactor synthesis: The import of thiamine and the conversion of thiamine to thiamine diphosphate via thiamine thiphosphokinase is essential in resistant parasites. Sensitive parasites can also synthesize thiamine diphosphate de novo. Arrows colored for flux via FVA and stars for essentiality. Gray background indicates cytosolic localization, yellow indicates mitochondrial localization. FVA, flux variability analysis. SHMT, serine hydroxylmethltransferase, mthf, methyltetrahydrofolate, thf, tetrahydrofolate

Additionally, we identified serine hydroxymethyltransferase (SHMT) and thiamine diphosphokinase as potential drug targets of resistant parasites (Table 5 , Fig. 5b & c); see below for discussion of SHMT. Both the import of thiamine and thiamine diphosphokinase are essential only in resistant parasites (Fig. 5c), and we predict inhibition of import or enzyme activity would specifically target resistant parasites. These reactions are relatively uncharacterized as the parasite can likely synthesize thiamine diphosphate (vitamin B1) de novo [117]. Thus, this approach can generate novel hypotheses and be utilized for the identification of novel drug targets, and, importantly, targets to help prevent the development of resistance.

Data-driven model implementation highlights knowledge gaps

Although iPfal17 represents our best understanding of intra-erythrocytic P. falciparum biochemistry as the most comprehensive reconstruction to date, predictions occasionally contradict published experimental results. These results illuminate experimental complexities and incompletely characterized pathways. For example, our model predicted that cytosolic SHMT is only essential in resistant parasites (Fig. 5b left). In sensitive parasites, the essential metabolites can be generated by SHMT or the mitochondrial glycine cleavage system, given the reversible nature of these enzymes [118, 119]. Therefore, in our sensitive models, neither SHMT nor the glycine cleavage system is essential when knocked out individually. This observation conflicts with the literature, as SHMT is essential in cultured parasites [118, 120, 121]. Thus, iPfal17 is unable to predict this intricacy of parasite metabolism, revealing interesting regulatory effects, an uncharacterized location dependency for metabolite generation, or in vivo/in vitro differences in enzyme reversibility (Additional file 6).

Similarly, model integration reveals that protein localization influences essentiality predictions. We predicted that the cyclical oxidization and reduction of glutathione, a key regulator of oxidative stress [122125], and supporting reactions were essential only in resistant parasites when the glutathione redox system was located within the mitochondria (data not shown). This is consistent with artemisinin’s induction of reactive oxygen species, the parasite’s obvious need to survive this stress [24, 3335], data showing artemisinin sensitivity is correlated with glutathione levels in rodent Plasmodium [27], and artemisinin’s inhibition of mammalian glutathione s-transferases [103]. However, upon moving these reactions to the cytosolic and apicoplast compartments (as supported by [126]), these reactions were no longer essential. Thus, model analysis challenges the integration of previously incomparable datasets by demonstrating that this localization and role of glutathione yield different predictions. Future studies will be required to clarify these findings.

Conclusions

Here, we have presented both a novel blood-stage-specific P. falciparum metabolic network reconstruction, iPfal17, and investigation of the metabolic differences between artemisinin sensitive and resistant parasites. Antimalarial resistance is a major public health problem and we demonstrate that constraint-based modeling can be used to reveal metabolic shifts that arise with or in support of the resistant phenotype and discrepancies between otherwise incomparable datasets. We find inherent differences in artemisinin resistant and sensitive parasite metabolism, even before artemisinin treatment. Artemisinin resistant parasites have major metabolic shifts in the mitochondria and in the synthesis of folates and polyamines, indicating incomplete transition to the metabolic state most appropriate for the blood-stage environment. These findings generate areas of future research to elucidate Plasmodium biochemistry, understand the evolution of artemisinin resistant parasites, and tackle antimalarial resistance.

Methods

Expression analysis

Normalized preprocessed data was obtained from GEO (GSE59097) [49]. Probes on the microarray platform GPL18893 were annotated using NCBI’s stand-alone BLAST correcting the gene labels for 647 probes. Only top hits were used; specifically, hits with greater than 95% identity, no gaps, and a score of over 100 were used (Additional file 3: Table S8). The R package limma was used to compare artemisinin sensitive and resistant samples collected from Cambodia and Vietnam [127]. Samples with predominantly ring-stage parasites with no detectable gametocytes were used. Resistant parasites were defined as both having at least one mutant Kelch13 allele and a parasite clearance half-life of greater than 5 h (Fig. 1) [49, 128]. Sensitive parasites were defined by having at least no mutant Kelch13 alleles and a parasite clearance half-life of less than 5 h. Random Forest classifiers were built using the R package randomForest, using all ring-stage samples [129]. The metadata classifier used the variables listed in Additional file 2: Figure S2, as outlined in the original study [49]. Cambodian and Vietnamese ring-stage transcriptomes were compared separately to ensure patterns associated with resistance status were reproducible across phylogenies. These countries were chosen for large number of isolates and prevalence of resistance. Microarray probes were screened to remove non-metabolic genes and to keep only one probe per gene (consistent with standard practice). Multiple testing correction was conducted using a false discovery rate [130, 131].

Gene expression data with calculations of fold changes and associated adjusted p-value were incorporated into our curated model using the Metabolic Adjustment for Differential Expression (MADE) algorithm. MADE utilizes statistical significance of gene expression changes along with network context to assign binary gene states (‘on’/‘off’) to each metabolic gene. This constrains the network by limiting flux through reactions mapped to ‘off’ genes while maintaining growth, or a similar objective. An 80% growth threshold was used given that there is no reported evidence that resistant and sensitive parasites produce variable biomass as measured by the size of ring-stage parasites; while varying this threshold affects sensitive parasite biomass yield, it does not affect essentiality predictions (data not shown). Essential genes were predicted for the resultant condition-specific models (Fig. 3) by conducting single gene and reaction deletions with established algorithms [132]. Consensus lethal gene and reaction deletions from the Cambodian and Vietnamese parasite models were used.

Flux analysis and metabolic tasks

Flux balance analysis (FBA) is an approach to explore metabolic phenotypes in silico [133]. FBA simulates steady-state flux values for each of the network’s reactions that maximize subsequent flux through an objective function given a set of constraints. We chose biomass production as the objective reaction, consistent with previous studies interrogating gene essentiality [50, 53, 79, 134], and permitted flux through all transport reactions. Constraints on the system include conservation of mass, reversibility of reactions, and reaction localization. Flux variability analysis (FVA) uses a related approach to find the range of fluxes permissible given system constraints [135].

We simulated in vitro experiments and in vivo data to evaluate the model; these are our metabolic ‘tasks’ that the reconstruction should pass. We simulate in vitro growth requirements by modifying media components or access to particular metabolites. Metabolite import or production was eliminated from the reconstruction, and subsequent biomass production was observed. Effects of enzyme inhibition, gene knockouts, and metabolite production were also used to evaluate the model. Lethal modifications were defined as changes that resulted in no production of biomass; growth-reducing modifications were defined as producing less than 90% of unconstrained flux value [81, 134].

The COBRA Toolbox 2015, Tiger Toolbox (version 1.3.1), and MATLAB R2013b were used for model generation and flux simulations.

Curation

Manual curation of an existing P. falciparum metabolic network reconstruction [50] was conducted by a literature review and reference to generic and Plasmodium-specific databases (KEGG, Expasy, and PlasmoDB, MPMP) [43, 136138]. Data obtained from these sources were used to evaluate the inclusion of reactions as well as their stoichiometry, reversibility, localization, and gene annotations. Genetically and biochemically supported reactions were kept and new reactions were added. Reactions were removed if (1) explicitly determined to be false or (2) were nonfunctional and not supported biochemically or genetically. Spontaneous reactions (reactions that occur without enzymes) are noted to differentiate from orphan reactions (reactions with unknown enzyme catalysts).

In order to assess gene essentiality, we used a biomass reaction as the modeling objective function. Thus, flux through this reaction, simulating cellular growth, was maximized for all in silico experimental procedures. We used the biomass reaction from a previous study [50] with modifications. Curation of the biomass reaction was informed by metabolites detected in metabolomics studies [28, 5658]; if possible, metabolite ratios were predicted from metabolomics data. We curated the biomass reaction with consideration of published essentiality data; metabolites detected in metabolomics experiments with no known catabolism or import pathways were excluded from the biomass reaction.

Essentiality studies

We predicted essentiality by performing single deletion studies with both genes and reactions and double gene deletion studies in our curated model and each expression-constrained sensitive and resistant models. All simulations were performed in an in silico red blood cell environment (Additional file 3: Table S9). Gene deletions were simulated by removing the gene of interest from the model. This change results in the inhibition of flux through all reactions that require that gene to function. If the model could not produce biomass with these constraints, the gene was deemed essential. Growth reducing phenotypes were also observed and noted. For reaction deletion studies, we removed reactions sequentially. Subsequent growth effects were used to determine reaction essentially. Consensus results for resistant or sensitive models are discussed.

Abbreviations

FBA: 

Flux balance analysis

FVA: 

Flux variability analysis

MADE: 

Metabolic Adjustment for Differential Expression algorithm

SHMT: 

serine hydroxymethyltransferase

TCA: 

tricarboxylic acid cycle

Declarations

Acknowledgements

We acknowledge the members of the Guler, Papin, and Petri labs for their thoughtful conversations and insight. We would also like to thank Dr. Paul Jensen, Dr. Edik Blais, and Gregory Medlock for project feedback.

Funding

The study was financed by institutional funding from the University of Virginia (JG) and by the National Institute of Allergy and Infectious Disease R21AI119881 (JG and JP). MC is supported by an institutional training grant (T32GM008136).

Availability of data and materials

The supporting data and materials of this article are included within the article and additional files; additionally, our model and code is available on https://github.com/gulermalaria/iPfal17.

Authors’ contributions

MC, JG, and JP designed the study. MC curated the model and performed metabolic network, statistical, and machine learning analyses. All the authors participated in data interpretation, and read and approved the manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, School of Medicine, Charlottesville, USA
(2)
Department of Biomedical Engineering, University of Virginia, Charlottesville, USA
(3)
Department of Biology, University of Virginia, Charlottesville, USA
(4)
Division of Infectious Diseases and International Health, University of Virginia, School of Medicine, Charlottesville, USA

References

  1. Schwartz, E. and T. Lachish, Artemisinin-based combination therapy (ACT) versus atovaquone-proguanil: do not choose between but, rather, combine them. Evidence Based Medicine, 2016. 21(2): p. 64–64.Google Scholar
  2. Olliaro PL, Taylor WR. Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: a review. J Postgrad Med. 2004;50(1):40.PubMedGoogle Scholar
  3. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol. 2009;7(12):864–74.PubMedPubMed CentralGoogle Scholar
  4. Chakraborty A. Emerging drug resistance in plasmodium falciparum: a review of well-characterized drug targets for novel antimalarial chemotherapy. Asian Pac J of Tro Dis. 2016;6(7):581–8.View ArticleGoogle Scholar
  5. Cowman AF, et al. Malaria: biology and disease. Cell. 2016;167(3):610–24.PubMedView ArticleGoogle Scholar
  6. Plowe CV, et al. World antimalarial resistance network (WARN) III: molecular markers for drug resistant malaria. Malar J. 2007;6(1):1–10.View ArticleGoogle Scholar
  7. Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance in plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science. 2002;298Google Scholar
  8. Guler JL, et al. Atovaquone tolerance in plasmodium falciparum parasites selected for high-level resistance to a dihydroorotate dehydrogenase inhibitor. Antimicrob Agents Chemother. 2015;59(1):686–9.PubMedView ArticleGoogle Scholar
  9. Herman JD, et al. A genomic and evolutionary approach reveals non-genetic drug resistance in malaria. Genome Biol. 2014;15(11):511.Google Scholar
  10. Gabryszewski, S.J., et al., Evolution of Fitness Cost-Neutral Mutant PfCRT Conferring P. falciparum 4-Aminoquinoline Drug Resistance Is Accompanied by Altered Parasite Metabolism and Digestive Vacuole Physiology. PLOS Pathog, 2016. 12(11): p. e1005976.Google Scholar
  11. Meylan S, et al. Carbon sources tune antibiotic susceptibility in Pseudomonas Aeruginosa via tricarboxylic acid cycle control. Cell Chem Biol. 2017; 24:195-206.Google Scholar
  12. El-Halfawy OM, Valvano MA. Non-genetic mechanisms communicating antibiotic resistance: rethinking strategies for antimicrobial drug design. Expert Opin Drug Discov. 2012;7(10):923–33.PubMedView ArticleGoogle Scholar
  13. Ashley EA, et al. Spread of artemisinin resistance in plasmodium falciparum malaria. N Engl J Med. 2014;371(5):411–23.PubMedPubMed CentralView ArticleGoogle Scholar
  14. Miotto O, et al. Genetic architecture of artemisinin-resistant plasmodium falciparum. Nat Genet. 2015;47(3):226–34.PubMedPubMed CentralView ArticleGoogle Scholar
  15. Straimer J, et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015;347(6220):428–31.PubMedView ArticleGoogle Scholar
  16. Ariey F, et al. A molecular marker of artemisinin-resistant plasmodium falciparum malaria. Nature. 2014;505(7481):50–5.PubMedView ArticleGoogle Scholar
  17. Brown TS, et al. Plasmodium falciparum field isolates from areas of repeated emergence of drug resistant malaria show no evidence of hypermutator phenotype. Infection, Genetics and Evolution: J Mol Epidemiol Evol Genet Infect Dis. 2015;30:318–22.View ArticleGoogle Scholar
  18. Cheng Q, Kyle DE, Gatton ML. Artemisinin resistance in Plasmodium falciparum: A process linked to dormancy? International Journal for parasitology. Drugs and Drug Resist. 2012;2:249–55.View ArticleGoogle Scholar
  19. Codd A, et al. Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure. Malar J. 2011;10Google Scholar
  20. Straimer J, et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Sci. 2015;347(6220):428–31.View ArticleGoogle Scholar
  21. Mbengue A, et al. A molecular mechanism of artemisinin resistance in plasmodium falciparum malaria. Nat. 2015;520(7549):683–7.View ArticleGoogle Scholar
  22. Ying-Zi Y, Little B, Meshnick SR. Alkylation of proteins by artemisinin: effects of heme, pH, and drug structure. Biochem Pharmacol. 1994;48(3):569–73.View ArticleGoogle Scholar
  23. Dalal S, Klemba M. Amino acid efflux by asexual blood-stage plasmodium falciparum and its utility in interrogating the kinetics of hemoglobin endocytosis and catabolism in vivo. Mol Biochem Parasitol. 2015;201(2):116–22.PubMedPubMed CentralView ArticleGoogle Scholar
  24. Klonis N, et al. Artemisinin activity against plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A. 2011;108(28):11405–10.PubMedPubMed CentralView ArticleGoogle Scholar
  25. Wang J, et al. Artemisinin Directly Targets Malarial Mitochondria through Its Specific Mitochondrial Activation. PLoS One. 2010;5(3):e9582.Google Scholar
  26. Chen N, et al. Fatty acid synthesis and pyruvate metabolism pathways remain active in Dihydroartemisinin-induced dormant ring stages of plasmodium falciparum. Antimicrob Agents Chemother. 2014;58(8):4773–81.PubMedPubMed CentralView ArticleGoogle Scholar
  27. Vega-Rodríguez J, et al. Implications of glutathione levels in the plasmodium berghei response to chloroquine and artemisinin. PLoS One. 2015;10(5):e0128212.Google Scholar
  28. Cobbold SA, et al. Metabolic dysregulation induced in plasmodium falciparum by Dihydroartemisinin and other front-line antimalarial drugs. J Infect Dis. 2016;213(2):276–86.PubMedView ArticleGoogle Scholar
  29. Peatey CL, et al. Mitochondrial membrane potential in a small subset of artemisinin-induced dormant plasmodium falciparum parasites in vitro. J Infect Dis. 2015;212(3):426–34.PubMedView ArticleGoogle Scholar
  30. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol. 2002;32(13):1655–60.PubMedView ArticleGoogle Scholar
  31. Eckstein-Ludwig U, et al. Artemisinins target the SERCA of plasmodium falciparum. Nature. 2003;424(6951):957–61.PubMedView ArticleGoogle Scholar
  32. Golenser J, et al. Current perspectives on the mechanism of action of artemisinins. Int J Parasitol. 2006;36(14):1427–41.PubMedView ArticleGoogle Scholar
  33. Efferth T, Oesch F. Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. Biochem Pharmacol. 2004;68(1):3–10.PubMedView ArticleGoogle Scholar
  34. Antoine T, et al. Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential. J Antimicrob Chemother. 2014;69(4):1005–16.PubMedView ArticleGoogle Scholar
  35. Sun C, et al. Two distinct and competitive pathways confer the cellcidal actions of artemisinins. Microbial Cell. 2015;2(1):14–25.PubMedPubMed CentralView ArticleGoogle Scholar
  36. Li, W., et al., Yeast model uncovers dual roles of mitochondria in the action of artemisinin. PLoS Genet, 2005. 1(3): p. e36.Google Scholar
  37. Kamau E, et al. K13-propeller polymorphisms in plasmodium falciparum parasites from sub-Saharan Africa. J Infect Dis. 2015;211(8):1352–5.PubMedGoogle Scholar
  38. Isozumi R, et al. Novel mutations in K13 propeller Gene of artemisinin-resistant <i>plasmodium falciparum</i>. Emerg Infect Dis. 2015;21(3):490–2.PubMedPubMed CentralView ArticleGoogle Scholar
  39. Klonis N, et al. Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc Natl Acad Sci U S A. 2013;110(13):5157–62.PubMedPubMed CentralView ArticleGoogle Scholar
  40. Mok S, et al. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics. 2011:12(1).Google Scholar
  41. Teuscher F, et al. Artemisinin-induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J Infect Dis. 2010;202(9):1362–8.PubMedPubMed CentralView ArticleGoogle Scholar
  42. Witkowski B, et al. Increased tolerance to artemisinin in plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob Agents Chemother. 2010;54(5):1872–7.PubMedPubMed CentralView ArticleGoogle Scholar
  43. Collaborativea TPGD, PlasmoDB: An integrative database of the Plasmodium falciparum genome. Tools for accessing and analyzing finished and unfinished sequence data. Nucleic Acids Res. 2001;29(1):66–9.Google Scholar
  44. Fidock DA, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000:6.Google Scholar
  45. Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A. 1988;85(23):9114-9118.Google Scholar
  46. Siregar JE, et al. Direct evidence for the atovaquone action on the plasmodium cytochrome bc1 complex. Parasitol Int. 2015;64(3):295–300.PubMedView ArticleGoogle Scholar
  47. Phillips MA, Rathod PK. Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infect Disord Drug Targets. 2010;10(3):226–39.PubMedPubMed CentralView ArticleGoogle Scholar
  48. Fuhrer T, et al. Genomewide landscape of gene–metabolome associations in Escherichia coli. Mol Syst Biol. 2017;13(1):907.Google Scholar
  49. Mok S, et al. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science. 2015;347(6220):431–5.PubMedView ArticleGoogle Scholar
  50. Plata G, et al. Reconstruction and flux-balance analysis of the plasmodium falciparum metabolic network. Mol Syst Biol. 2010;6Google Scholar
  51. Painter HJ, et al. Specific role of mitochondrial electron transport in blood-stage plasmodium falciparum. Nature. 2007;446(7131):88–91.PubMedView ArticleGoogle Scholar
  52. Langer RC, Vinetz JM. Plasmodium ookinete-secreted chitinase and parasite penetration of the mosquito peritrophic matrix. Trends Parasitol. 2001;17(6):269–72.Google Scholar
  53. Thiele I, Palsson BO. A protocol for generating a high-quality genome-scale metabolic reconstruction. Nat Protocols. 2010;5(1):93–121.PubMedView ArticleGoogle Scholar
  54. Sturm A, et al. Mitochondrial ATP synthase is dispensable in blood-stage plasmodium berghei rodent malaria but essential in the mosquito phase. Proc Natl Acad Sci. 2015;112(33):10216–23.PubMedPubMed CentralView ArticleGoogle Scholar
  55. Ginsburg H. Abundant proton pumping in plasmodium, but why? Trends Parasitol. 2002;18(11):483–6.PubMedView ArticleGoogle Scholar
  56. Gulati S, et al. Profiling the essential nature of lipid metabolism in asexual blood and gametocyte stages of plasmodium falciparum. Cell Host Microbe. 2015;18(3):371–81.PubMedPubMed CentralView ArticleGoogle Scholar
  57. Olszewski KL, et al. Host-parasite interactions revealed by plasmodium falciparum metabolomics. Cell Host Microbe. 2009;5(2):191–9.PubMedPubMed CentralView ArticleGoogle Scholar
  58. Sana TR, et al. Global Mass Spectrometry Based Metabolomics Profiling of Erythrocytes Infected with Plasmodium falciparum. PLoS One. 2013;8(4):e60840.Google Scholar
  59. Biddau M, Müller S. Carbon Metabolism of Plasmodium falciparum. Compr Anal Parasite Biol: Metab to Drug Discov. 2016:371.Google Scholar
  60. Ke H, et al. Genetic investigation of tricarboxylic acid metabolism during the plasmodium falciparum life cycle. Cell Rep. 2015;11(1):164–74.PubMedPubMed CentralView ArticleGoogle Scholar
  61. MacRae JI, et al. Mitochondrial metabolism of sexual and asexual blood stages of the malaria parasite plasmodium falciparum. BMC Biol. 2013;11(1):67.Google Scholar
  62. Yeh I. Computational analysis of plasmodium falciparum metabolism: organizing genomic information to facilitate drug discovery. Genome Res. 2004;14(5):917–24.PubMedPubMed CentralView ArticleGoogle Scholar
  63. Liu J, et al. Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proc Natl Acad Sci U S A. 2006;103(23):8840–5.PubMedPubMed CentralView ArticleGoogle Scholar
  64. Krugliak M, Zhang J, Ginsburg H. Intraerythrocytic plasmodium falciparum utilizes only a fraction of the amino acids derived from the digestion of host cell cytosol for the biosynthesis of its proteins. Mol Biochem Parasitol. 2002;119(2):249–56.PubMedView ArticleGoogle Scholar
  65. Asahi H, et al. Hypoxanthine: a low molecular weight factor essential for growth of erythrocytic plasmodium falciparum in a serum-free medium. Parasitol. 1996;113(01):19–23.View ArticleGoogle Scholar
  66. Geary TG, et al. Nutritional requirements of plasmodium falciparum in culture. III. Further observations on essential nutrients and antimetabolites. The J Protozool. 1985;32(4):608–13.PubMedView ArticleGoogle Scholar
  67. Miller LH, et al. The pathogenic basis of malaria. Nature. 2002;415(6872):673–9.PubMedView ArticleGoogle Scholar
  68. Geary TG, Divo AA, Jensen JB. Nutritional requirements of plasmodium falciparum in culture. II. Effects of antimetabolites in a semi defined medium. The J Protozool. 1985;32(1):65–9.PubMedView ArticleGoogle Scholar
  69. Jensen PA, Papin JA. Functional integration of a metabolic network model and expression data without arbitrary thresholding. Bioinform. 2011;27(4):541–7.View ArticleGoogle Scholar
  70. Fang X, Reifman J, Wallqvist A. Modeling metabolism and stage-specific growth of plasmodium falciparum HB3 during the intraerythrocytic developmental cycle. Mol BioSyst. 2014;10(10):2526–37.PubMedView ArticleGoogle Scholar
  71. Chiappino-Pepe A, et al. Bioenergetics-based modeling of plasmodium falciparum metabolism reveals its essential genes, nutritional requirements, and thermodynamic bottlenecks. PLoS Comput Biol. 2017;13(3):e1005397.PubMedPubMed CentralView ArticleGoogle Scholar
  72. Wallqvist A, et al. Metabolic host responses to malarial infection during the intraerythrocytic developmental cycle. BMC Syst Biol. 2016;10(1):58.PubMedPubMed CentralView ArticleGoogle Scholar
  73. Tymoshenko S, et al. Functional genomics of plasmodium falciparum using metabolic modelling and analysis. Briefings in Functional Genomics. 2013;12(4):316–27.PubMedPubMed CentralView ArticleGoogle Scholar
  74. Bazzani S, Hoppe A, Holzhütter H-G. Network-based assessment of the selectivity of metabolic drug targets in Plasmodium falciparum with respect to human liver metabolism. BMC Syst Biol. 2012:6(1).Google Scholar
  75. Aurrecoechea, C., et al., EuPathDB: the eukaryotic pathogen genomics database resource. Nucleic Acids Res, 2017: 45:D581-D591.Google Scholar
  76. Gardner MJ, et al. Genome sequence of the human malaria parasite plasmodium falciparum. Nat. 2002;419(6906):498–511.View ArticleGoogle Scholar
  77. Gajria B, et al. ToxoDB: an integrated Toxoplasma gondii database resource. Nucleic Acids Res. 2008;36(Database issue):D553–6.PubMedGoogle Scholar
  78. Xia D, et al. The proteome of Toxoplasma gondii: integration with the genome provides novel insights into gene expression and annotation. Genome Biol. 2008;9(7):R116.PubMedPubMed CentralView ArticleGoogle Scholar
  79. Tymoshenko S, et al. Metabolic needs and capabilities of <italic>Toxoplasma gondii </italic> through combined Computational and experimental analysis. PLoS Comput Biol. 2015;11(5):e1004261.PubMedPubMed CentralView ArticleGoogle Scholar
  80. Ivens AC, et al. The genome of the Kinetoplastid parasite, Leishmania major. Sci. 2005;309(5733):436.View ArticleGoogle Scholar
  81. Chavali AK, et al. Systems analysis of metabolism in the pathogenic trypanosomatid Leishmania major. Mol Syst Biol. 2008;4(1):177.PubMedPubMed CentralGoogle Scholar
  82. Orth, J.D., et al., A comprehensive genome-scale reconstruction of Escherichia coli metabolism—2011. Mol Syst Biol, 2011. 7: p. 535–535.Google Scholar
  83. Heavner BD, Price ND. Comparative analysis of yeast metabolic network models highlights progress, opportunities for metabolic reconstruction. PLoS Comput Biol. 2015;11(11):e1004530.PubMedPubMed CentralView ArticleGoogle Scholar
  84. McConville M. Open questions: microbes, metabolism and host-pathogen interactions. BMC Biol. 2014;12(1):18.Google Scholar
  85. Wellems TE, Fairhurst RM. An evolving picture of the interactions between malaria parasites and their host erythrocytes. Cell Res. 2012;22(3):453–6.PubMedPubMed CentralView ArticleGoogle Scholar
  86. Imlay L, Odom AR. Isoprenoid metabolism in apicomplexan parasites. Current Clinical Microbiology Reports. 2014;1(3–4):37–50.PubMedPubMed CentralView ArticleGoogle Scholar
  87. Mazumdar J, Striepen B. Make it or take it: fatty acid metabolism of apicomplexan parasites. Eukaryot Cell. 2007;6(10):1727–35.PubMedPubMed CentralView ArticleGoogle Scholar
  88. Lanzer M, et al. Maurer's clefts: a novel multi-functional organelle in the cytoplasm of plasmodium falciparum-infected erythrocytes. Int J Parasitol. 2006;36(1):23–36.PubMedView ArticleGoogle Scholar
  89. Bannister LH, et al. A brief illustrated guide to the ultrastructure of plasmodium falciparum asexual blood stages. Parasitol Today. 2000;16(10):427–33.PubMedView ArticleGoogle Scholar
  90. Baumeister S, et al. Evidence for the involvement of plasmodium falciparum proteins in the formation of new permeability pathways in the erythrocyte membrane. Mol Microbiol. 2006;60(2):493–504.PubMedView ArticleGoogle Scholar
  91. Ginsburg H, et al. New permeability pathways induced in membranes of plasmodium falciparum infected erythrocytes. Mol Biochem Parasitol. 1983;8(2):177–90.PubMedView ArticleGoogle Scholar
  92. Staines HM, et al. Solute transport via the new permeability pathways in plasmodium falciparum–infected human red blood cells is not consistent with a simple single-channel model. Blood. 2006;108(9):3187–94.PubMedPubMed CentralView ArticleGoogle Scholar
  93. Divo AA, et al. Nutritional requirements of plasmodium falciparum in culture. I. Exogenously supplied dialyzable components necessary for continuous growth. J Protozool. 1985;32(1):59–64.PubMedView ArticleGoogle Scholar
  94. Phaiphinit S, et al. In silico multiple-targets identification for heme detoxification in the human malaria parasite plasmodium falciparum. Infect Genet Evol. 2016;37:237–44.PubMedView ArticleGoogle Scholar
  95. Ghorbal M, et al. Genome editing in the human malaria parasite plasmodium falciparum using the CRISPR-Cas9 system. Nat Biotech. 2014;32(8):819–21.View ArticleGoogle Scholar
  96. Lee MCS, Fidock DA. CRISPR-mediated genome editing of plasmodium falciparum malaria parasites. Genome Med. 2014;6(8):63.PubMedPubMed CentralView ArticleGoogle Scholar
  97. Wagner JC, et al. Efficient CRISPR-Cas9-mediated genome editing in plasmodium falciparum. Nat Meth. 2014;11(9):915–8.View ArticleGoogle Scholar
  98. Lu J, et al. A redesigned CRISPR/Cas9 system for marker-free genome editing in plasmodium falciparum. Parasit Vectors. 2016;9(1):1.View ArticleGoogle Scholar
  99. Ramya TNC, et al. Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in plasmodium falciparum. Antimicrob Agents Chemother. 2007;51(1):307–16.PubMedView ArticleGoogle Scholar
  100. Ke H, et al. The heme biosynthesis pathway is essential for plasmodium falciparum development in mosquito stage but not in blood stages. J Biol Chem. 2014;289(50):34827–37.PubMedPubMed CentralView ArticleGoogle Scholar
  101. Nagaraj VA, et al. Malaria parasite-synthesized Heme is essential in the mosquito and liver stages and complements host Heme in the blood stages of infection. PLoS Pathog. 2013;9(8):e1003522.PubMedPubMed CentralView ArticleGoogle Scholar
  102. Ho M-C, et al. Structural and metabolic specificity of methylthiocoformycin for malarial adenosine deaminases. Biochemistry. 2009;48(40):9618–26.PubMedPubMed CentralView ArticleGoogle Scholar
  103. Zhou Y, Li W, Xiao Y. Profiling of multiple targets of artemisinin activated by hemin in cancer cell proteome. ACS Chem Biol. 2016;11(4):882–8.PubMedView ArticleGoogle Scholar
  104. Ismail HM, et al. Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites plasmodium falciparum 3D7. Proc Natl Acad Sci. 2016;113(8):2080–5.PubMedPubMed CentralView ArticleGoogle Scholar
  105. Prieto JH, et al. Large-Scale Differential Proteome Analysis in Plasmodium falciparum under Drug Treatment. PLoS One. 2008;3(12):e4098.Google Scholar
  106. Creek DJ, et al. Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action. Antimicrob Agents Chemother. 2016;60(11):6650–63.PubMedPubMed CentralView ArticleGoogle Scholar
  107. Pretzel J, et al. Characterization and redox regulation of plasmodium falciparum methionine adenosyltransferase. J Biochem. 2016;160(6):355–67.PubMedView ArticleGoogle Scholar
  108. Salcedo-Sora JE, et al. The molecular basis of folate salvage in plasmodium falciparum characterization of two folate transporters. J Biol Chem. 2011;286(52):44659–68.PubMedPubMed CentralView ArticleGoogle Scholar
  109. Wishart DS, et al. HMDB: the human metabolome database. Nucleic Acids Res. 2007;35(suppl 1):D521–6.PubMedPubMed CentralView ArticleGoogle Scholar
  110. Wang J, et al. Haem-activated promiscuous targeting of artemisinin in plasmodium falciparum. Nat Commun. 2015;6:10111.PubMedPubMed CentralView ArticleGoogle Scholar
  111. Singh S, et al. Characterization of Simian malarial parasite (plasmodium knowlesi)-induced putrescine transport in rhesus monkey erythrocytes a NOVEL PUTRESCINE CONJUGATE ARRESTS IN VITRO GROWTH OF SIMIAN MALARIAL PARASITE (PLASMODIUM KNOWLESI) AND CURES MULTIDRUG RESISTANT MURINE MALARIA (Plasmodium YOELII) INFECTION IN VIVO. J Biol Chem. 1997;272(21):13506–11.PubMedView ArticleGoogle Scholar
  112. Assaraf YG, et al. Effect of polyamine depletion on macromolecular synthesis of the malarial parasite, plasmodium falciparum, cultured in human erythrocytes. Biochem J. 1987;242(1):221–6.PubMedPubMed CentralView ArticleGoogle Scholar
  113. Stevens L. The biochemical role of naturally occurring polyamines in nucleic acid synthesis. Biol Rev. 1970;45(1):1–25.PubMedView ArticleGoogle Scholar
  114. Mandal S, et al. Depletion of cellular polyamines, spermidine and spermine, causes a total arrest in translation and growth in mammalian cells. Proc Natl Acad Sci. 2013;110(6):2169–74.PubMedPubMed CentralView ArticleGoogle Scholar
  115. Teuscher F, et al. Phenotypic changes in artemisinin-resistant plasmodium falciparum lines in vitro: evidence for decreased sensitivity to dormancy and growth inhibition. Antimicrob Agents Chemother. 2012;56(1):428–31.PubMedPubMed CentralView ArticleGoogle Scholar
  116. Srivastava A, et al. Stage-specific changes in plasmodium metabolism required for differentiation and adaptation to different host and vector environments. PLoS Pathog. 2016;12(12):e1006094.PubMedPubMed CentralView ArticleGoogle Scholar
  117. Müller S, Kappes B. Vitamin and cofactor biosynthesis pathways in plasmodium and other apicomplexan parasites. Trends Parasitol. 2007;23(3):112–21.PubMedPubMed CentralView ArticleGoogle Scholar
  118. Maenpuen S, et al. Characterization of plasmodium falciparum serine hydroxymethyltransferase—a potential antimalarial target. Mol Biochem Parasitol. 2009;168(1):63–73.PubMedView ArticleGoogle Scholar
  119. Salcedo E, Sims PFG, Hyde JE. A glycine-cleavage complex as part of the folate one-carbon metabolism of plasmodium falciparum. Trends Parasitol. 2005;21(9):406–11.PubMedPubMed CentralView ArticleGoogle Scholar
  120. Pornthanakasem W, et al. Plasmodium serine hydroxymethyltransferase: indispensability and display of distinct localization. Malar J. 2012;11(1):387.PubMedPubMed CentralView ArticleGoogle Scholar
  121. França TCC, Pascutti PG, Ramalho TC. A three-dimensional structure of plasmodium falciparum serine hydroxymethyltransferase in complex with glycine and 5-formyl-tetrahydrofolate. Homology modeling and molecular dynamics. Biophys Chem. 2005;115(1):1–10.PubMedView ArticleGoogle Scholar
  122. Schulz JB, et al. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem. 2000;267(16):4904–11.PubMedView ArticleGoogle Scholar
  123. Mittler R. Oxidative stress, antioxidants and stress tolerance. Trends Plant Sci. 2002;7(9):405–10.PubMedView ArticleGoogle Scholar
  124. Becker K, et al. Oxidative stress in malaria parasite-infected erythrocytes: host–parasite interactions. Int J Parasitol. 2004;34(2):163–89.PubMedView ArticleGoogle Scholar
  125. Färber PM, et al. Molecular cloning and characterization of a putative glutathione reductase gene, the PfGR2 gene, from plasmodium falciparum. Eur J Biochem. 1996;239(3):655–61.PubMedView ArticleGoogle Scholar
  126. Kehr S, et al. Compartmentation of redox metabolism in malaria parasites. PLoS Pathog. 2010;6(12):e1001242.PubMedPubMed CentralView ArticleGoogle Scholar
  127. Ritchie, M.E., et al., Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 2015. 43(7): p. e47-e47.Google Scholar
  128. White LJ, et al. Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach. PLoS Med. 2015;12(4):e1001823.Google Scholar
  129. Liaw A, Wiener M. Classification and regression by randomForest. R News. 2002;2(3):18–22.Google Scholar
  130. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. Series B (Methodological). 1995:289–300.Google Scholar
  131. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001:1165–88.Google Scholar
  132. Becker SA, et al. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA toolbox. Nat Protoc. 2007;2Google Scholar
  133. Orth JD, Thiele I, Palsson BO. What is flux balance analysis? Nat Biotech. 2010;28(3):245–8.View ArticleGoogle Scholar
  134. Oberhardt MA, et al. Metabolic network analysis of Pseudomonas Aeruginosa during chronic cystic fibrosis lung infection. J Bacteriol. 2010;192Google Scholar
  135. Gudmundsson S, Thiele I. Computationally efficient flux variability analysis. BMC Bioinform. 2010;11(1):489.View ArticleGoogle Scholar
  136. Kanehisa M, et al. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44(D1):D457–62.PubMedView ArticleGoogle Scholar
  137. Gasteiger E, et al. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 2003;31(13):3784–8.PubMedPubMed CentralView ArticleGoogle Scholar
  138. Ginsburg H. Progress in in silico functional genomics: the malaria metabolic pathways database. Trends Parasitol. 2006;22(6):238–40.PubMedView ArticleGoogle Scholar
  139. Yeh E, DeRisi JL. Chemical Rescue of Malaria Parasites Lacking an Apicoplast Defines Organelle Function in Blood-Stage Plasmodium falciparum. PLoS Biol. 2011;9(8):e1001138.Google Scholar
  140. Woodrow CJ, Burchmore RJ, Krishna S. Hexose permeation pathways in plasmodium falciparum-infected erythrocytes. Proc Natl Acad Sci U S A. 2000;97(18):9931–6.PubMedPubMed CentralView ArticleGoogle Scholar
  141. Anfinsen CB, et al. STUDIES ON MALARIAL PARASITES : VIII. FACTORS AFFECTING THE GROWTH OF PLASMODIUM KNOWLESI IN VITRO. J Exp Med. 1946;84(6):607–21.PubMedPubMed CentralView ArticleGoogle Scholar
  142. Jiang L, et al. Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against plasmodium falciparum. Antimicrob Agents Chemother. 2000;44(4):1047–50.PubMedPubMed CentralView ArticleGoogle Scholar
  143. Yu M, et al. The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe. 2008;4(6):567–78.PubMedPubMed CentralView ArticleGoogle Scholar
  144. Vaughan AM, et al. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell Microbiol. 2009;11(3):506–20.PubMedView ArticleGoogle Scholar
  145. Deng X, et al. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds. J Biol Chem. 2009;284(39):26999–7009.PubMedPubMed CentralView ArticleGoogle Scholar
  146. McRobert L, McConkey GA. RNA interference (RNAi) inhibits growth of plasmodium falciparum. Mol Biochem Parasitol. 2002;119(2):273–8.PubMedView ArticleGoogle Scholar
  147. Nguyen, C., et al., Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target. (0022–2623 (Print)).Google Scholar
  148. Thornalley, P.J., R.J. Strath M Fau - Wilson, and R.J. Wilson, Antimalarial activity in vitro of the glyoxalase I inhibitor diester, S-p-bromobenzylglutathione diethyl ester. (0006–2952 (Print)).Google Scholar
  149. Hanada K, et al. Plasmodium falciparum phospholipase C hydrolyzing sphingomyelin and lysocholinephospholipids is a possible target for malaria chemotherapy. J Exp Med. 2002;195(1):23–34.PubMedPubMed CentralView ArticleGoogle Scholar
  150. Silva, A.M., et al., Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. (0027–8424 (Print)).Google Scholar
  151. Hoepfner D, et al. Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe. 2012;11(6):654–63.PubMedPubMed CentralView ArticleGoogle Scholar
  152. Patzewitz EM, Wong EH, Muller S. Dissecting the role of glutathione biosynthesis in plasmodium falciparum. Mol Microbiol. 2012;83(2):304–18.PubMedPubMed CentralView ArticleGoogle Scholar
  153. Sturm N, et al. Identification of proteins targeted by the thioredoxin superfamily in plasmodium falciparum. PLoS Pathog. 2009;5(4):e1000383.PubMedPubMed CentralView ArticleGoogle Scholar
  154. Belorgey D, Lanfranchi DA, Davioud-Charvet E. 1,4-naphthoquinones and other NADPH-dependent glutathione reductase-catalyzed redox cyclers as antimalarial agents. Curr Pharm Des. 2013;19(14):2512–28.PubMedPubMed CentralView ArticleGoogle Scholar
  155. Muller S. Role and regulation of glutathione metabolism in plasmodium falciparum. Mol. 2015;20(6):10511–34.View ArticleGoogle Scholar
  156. Pastrana-Mena R, et al. Glutathione reductase-null malaria parasites have normal blood stage growth but arrest during development in the mosquito. J Biol Chem. 2010;285(35):27045–56.PubMedPubMed CentralView ArticleGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement